OGEN vs OKYO

Oragenics Inc. vs OKYO Pharma Limited — Valuation Comparison 2026

OGEN

Biotechnology
Oragenics Inc.
Quality
4.5
out of 10
Value Trap
12
SAFE
Price
$0.60
Last close
Models
6/13
Active
VS

OKYO

Biotechnology
OKYO Pharma Limited
Quality
1.7
out of 10
Value Trap
Price
$1.71
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType OGEN Fair ValueOGEN Upside OKYO Fair ValueOKYO Upside
Bayesian DCF Intrinsic $0.90 +49.9% $0.45 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.14 -76.9% $1.29 -24.5%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $0.85 +41.5% $1.04 -38.7%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for OGEN vs OKYO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OGEN vs OKYO — Which Stock Is More Undervalued?

OGEN scores higher with a 4.5/10 quality rating vs OKYO's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Oragenics Inc. (OGEN) and OKYO Pharma Limited (OKYO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OGEN currently trades at $0.60 with a QOC of 4.5/10, while OKYO trades at $1.71 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).